Prostate cancer (PCA) and lower urinary tract symptoms (LUTS) associated with aging and benign prostatic hyperplasia are ubiquitous in aging men. PCA has a high prevalence, causes considerable morbidity when metastatic, and is the third most common cause of cancer death in men (1). LUTS adversely affects quality of life and may result in recurrent infections and urinary retention, leading to morbidity and mortality among older men.

中文翻译：

---

5α-还原酶抑制剂可降低前列腺癌的风险

与衰老和良性前列腺增生相关的前列腺癌（PCA）和下尿路症状（LUTS）在衰老男性中无处不在。PCA的患病率很高，转移时会引起较高的发病率，并且是男性癌症死亡的第三大最常见原因（1）。LUTS对生活质量产生不利影响，并可能导致反复感染和尿retention留，从而导致老年男性发病和死亡。